Radioligand therapies for cancer

Data derived from two of our recently designed radioligand therapies is shown below.  The first, a single dose of our FAP9-targeted ¹⁷⁷Lu radiotherapy is shown to control PANC-1 tumors in mice, while the second, a single dose of three different versions of our bone metastasis-targeted ¹⁷⁷Lu radiotherapy is shown to control prostate cancer metastases (implants) to the bone, as measured by serum PSA levels.  Several other radioligand therapies are also under development.